Crocs (CROX)
(Delayed Data from NSDQ)
$133.50 USD
+1.95 (1.48%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $133.45 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
CROX 133.50 +1.95(1.48%)
Will CROX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CROX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CROX
Aaron's (AAN) Announces Opening of New BrandsMart Store
Crocs (CROX) Maintains Brand Relevance: Is This Behind Its Rally?
CROX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crocs (CROX) Rises But Trails Market: What Investors Should Know
Ralph Lauren's (RL) Digital & Other Moves Aid: Apt to Hold?
Spectrum Brands' (SPB) Pricing & Cost-Saving Actions on Track
Other News for CROX
Small and Mid-Cap stocks likely to beat/miss this earnings season - BofA
Crocs: Despite Some Challenges, This Shoemaker Is Widely Undervalued
Crocs, Inc. Announces Conference Call to Review Second Quarter 2024 Earnings Results
Crocs price target lowered by $2 at UBS, here's why
Nike’s Dismal Outlook Drags Other Athletic Product Stocks Lower